Fingolimod Hydrochloride API

Name	Fingolimod Hydrochloride
Chinese name	盐酸芬戈莫德
Cas Number	162359-56-0
Source	India
Qualifications	USDMF/-/-/-/-

Fingolimod hydrochloride is a modulator of sphingosine-1 phosphate receptors (S1PR1/S1PR3/S1PR4/S1PR5), which promotes the retention of lymphocytes in lymph nodes and achieves the effect of inhibiting autoimmune reactions. Fingolimod was developed by Novartis and was approved in the United States in September 2010. Its indication is multiple sclerosis (MS). At present, the product has been approved for marketing in the European Union, Canada, Japan and other countries. In July 2014, the European Union approved it for relapsing-remitting multiple sclerosis (RRMS) patients who did not respond to the injection of interferon beta. Fingolimod had sales of US$3.185 billion in 2017, which is a blockbuster product that cannot be ignored in the multiple sclerosis market. It is worth noting that in China, multiple sclerosis has been included in the "First List of Rare Diseases" in May 2018. In August last year, the Center for Drug Evaluation (CDE) of the State Food and Drug Administration issued 48 overseas clinical trials. The list of urgently needed new drugs also includes Novartis's fingolimod hydrochloride.

Hot Tags: fingolimod hydrochloride api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Gabapentin API, Vinpocetine API, Escitalopram Oxalate API, Fulvestrant API, Valganciclovir Hydrochloride API, Paliperidone API

• Previous: Bupivacaine Base API
• Next: Acotiamide API